<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:06:21Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5653652" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5653652</identifier><datestamp>2017-10-25</datestamp><setSpec>ncomms</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Commun</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id>
      <journal-title-group>
        <journal-title>Nature Communications</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2041-1723</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5653652</article-id>
      <article-id pub-id-type="pmcid">PMC5653652</article-id>
      <article-id pub-id-type="pmc-uid">5653652</article-id>
      <article-id pub-id-type="pmid">29061980</article-id>
      <article-id pub-id-type="publisher-id">1263</article-id>
      <article-id pub-id-type="doi">10.1038/s41467-017-01263-3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Structure of human lysosomal acid Î±-glucosidaseâa guide for the treatment of Pompe disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Roig-Zamboni</surname>
            <given-names>VÃ©ronique</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8211-2297</contrib-id>
          <name>
            <surname>Cobucci-Ponzano</surname>
            <given-names>Beatrice</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3586-4322</contrib-id>
          <name>
            <surname>Iacono</surname>
            <given-names>Roberta</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8905-2488</contrib-id>
          <name>
            <surname>Ferrara</surname>
            <given-names>Maria Carmina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Germany</surname>
            <given-names>Stanley</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bourne</surname>
            <given-names>Yves</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Parenti</surname>
            <given-names>Giancarlo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9846-2531</contrib-id>
          <name>
            <surname>Moracci</surname>
            <given-names>Marco</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4844-2820</contrib-id>
          <name>
            <surname>Sulzenbacher</surname>
            <given-names>Gerlind</given-names>
          </name>
          <address>
            <email>Gerlind.Sulzenbacher@afmb.univ-mrs.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1798 275X</institution-id><institution-id institution-id-type="GRID">grid.463764.4</institution-id><institution>Centre National de la Recherche Scientifique (CNRS), </institution><institution>Aix-Marseille Univ, AFMB, </institution></institution-wrap>163 Avenue de Luminy, 13288 Marseille, France </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1940 4177</institution-id><institution-id institution-id-type="GRID">grid.5326.2</institution-id><institution>Institute of Biosciences and Bioresources, </institution><institution>National Research Council of Italy, </institution></institution-wrap>Via P. Castellino 111, 80131 Naples, Italy </aff>
        <aff id="Aff3"><label>3</label>Telethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, Pozzuoli, 80078 Naples Italy </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0790 385X</institution-id><institution-id institution-id-type="GRID">grid.4691.a</institution-id><institution>Department of Translational Medical Sciences, </institution><institution>Federico II University, </institution></institution-wrap>Via Pansini 5, 80131 Naples, Italy </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0790 385X</institution-id><institution-id institution-id-type="GRID">grid.4691.a</institution-id><institution>Department of Biology, </institution><institution>Federico II University, Complesso Universitario di Monte S. Angelo, </institution></institution-wrap>Via Cintia 21, 80126 Naples, Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>10</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>24</day>
        <month>10</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2017</year>
      </pub-date>
      <volume>8</volume>
      <elocation-id>1111</elocation-id>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>6</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>9</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© The Author(s) 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the articleâs Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the articleâs Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">Pompe disease, a rare lysosomal storage disease caused by deficiency of the lysosomal acid Î±-glucosidase (GAA), is characterized by glycogen accumulation, triggering severe secondary cellular damage and resulting in progressive motor handicap and premature death. Numerous disease-causing mutations in the <italic>gaa</italic> gene have been reported, but the structural effects of the pathological variants were unknown. Here we present the high-resolution crystal structures of recombinant human GAA (rhGAA), the standard care of Pompe disease. These structures portray the unbound form of rhGAA and complexes thereof with active site-directed inhibitors, providing insight into substrate recognition and the molecular framework for the rationalization of the deleterious effects of disease-causing mutations. Furthermore, we report the structure of rhGAA in complex with the allosteric pharmacological chaperone N-acetylcysteine, which reveals the stabilizing function of this chaperone at the structural level.</p>
      </abstract>
      <abstract id="Abs2" abstract-type="web-summary">
        <p id="Par2">Pompe disease is caused by mutations in lysosomal acid Î±-glucosidase (GAA) and patients are being treated with recombinant human Î±-glucosidase (rhGAA). Here the authors present the crystal structures of rhGAA and its complexes with inhibitors and a pharmacological chaperone, which is important for drug development.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>Â© The Author(s) 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p id="Par3">Pompe disease (also known as glycogen storage disease type 2 or acid maltase deficiency) is an autosomal recessive disorder caused by mutations in the gene that encodes the hydrolase acid Î±-glucosidase (GAA), member of glycoside hydrolase family GH31<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, and involved in the lysosomal breakdown of glycogen. Functional deficiency of GAA results in lysosomal accumulation of glycogen and cellular damage in all tissues, particularly cardiac and skeletal muscle<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. Pompe disease is characterized by a broad phenotypic spectrum that ranges from a slowly progressing late-onset phenotype to a devastating classical infantile-onset, but in all cases, progressive muscle hypotonia and loss of motor, respiratory and cardiac functions leads to respiratory failure<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>. Recombinant human GAA (rhGAA) produced in CHO cells has been approved in 2006 for enzyme replacement therapy (ERT) to treat Pompe disease and has proven to be beneficial for patientâs survival and to stabilize the disease course<sup><xref ref-type="bibr" rid="CR5">5</xref>â<xref ref-type="bibr" rid="CR8">8</xref></sup>. Since then, ERT is the only approved treatment for Pompe disease, but despite the clinical benefits, patientâs response is very variable and the efficiency of the treatment is limited by insufficient targeting and uptake in muscle tissues, immunogenic reactions and build-up of autophagic compartments in myocytes<sup><xref ref-type="bibr" rid="CR9">9</xref>â<xref ref-type="bibr" rid="CR12">12</xref></sup>. Hence, the quest for alternative therapeutic strategies based on different approaches and rationale has become compulsory and pharmacological chaperone therapy (PCT) has been proposed as an alternative or complementary approach to ERT<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>. PCT is based on the concept that small-molecule ligands may act by blocking conformational fluctuations of a partially misfolded protein, rescuing its functional state and allowing escape from the endoplasmic reticulum-associated protein degradation (ERAD) machinery (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>)<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Hundreds of disease-causing mutations in the <italic>gaa</italic> gene have been identified, including insertions, deletions, splice site, nonsense, and missense mutations (Supplementary TableÂ <xref rid="MOESM1" ref-type="media">1</xref>). Missense mutations result in production of full-length GAA, likely to not fold as efficiently as the stable wild-type enzyme, and patients affected by these mutations are thus potential candidates for PCT<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. While not more than ~10â15% patients are estimated to be amenable to PCT<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, it has been shown that pharmacological chaperones act as enzyme enhancers when co-administered with rhGAA, by favoring enzyme delivery, stability and maturation<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, making this PCT independent from the type of mutation carried by patients.<fig id="Fig1"><label>Fig. 1</label><caption><p>The effect of pharmacological chaperones on misfolded lysosomal enzymes and on recombinant enzymes used in ERT. Lysosomal enzymes are assisted by molecular chaperones during synthesis. Mutated enzymes fail to fold correctly and are intercepted by the quality control (QC) system of the endoplasmic reticulum (ER). <bold>a</bold> Pharmacological chaperones favor proper folding of mutated enzymes, prevent their recognition by the quality control system and stabilize the enzyme during transport to their destination. <bold>b</bold> Pharmacological chaperones can enhance the effect of recombinant enzymes administered in ERT by favoring trafficking to lysosomes and increasing enzyme stability</p></caption><graphic xlink:href="41467_2017_1263_Fig1_HTML" id="d29e385"/></fig>
</p>
      <p id="Par4">Here we report the high-resolution structures of mature rhGAA and its complexes with the GAA inhibitors acarbose, 1-deoxynojirimycin (DNJ), N-hydroxyethyl-DNJ (NHE-DNJ) and with the allosteric pharmacological chaperone N-acetylcysteine<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. These structures give insight into substrate recognition, support at the molecular level the action of currently known pharmacological chaperones, and provide a molecular framework for the rationalization of mutations in clinical isolates of individuals affected by Pompe disease.</p>
    </sec>
    <sec id="Sec2" sec-type="results">
      <title>Results</title>
      <sec id="Sec3">
        <title>Structural overview</title>
        <p id="Par5">GAA is synthesized as a 110âkDa glycoprotein, which is targeted to the lysosome via the mannose-6-phosphate receptor and undergoes in the late endosomal/lysosomal compartment a series of proteolytic and N-glycan processing events to yield a mature active form composed of four tightly associated peptides<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. Because crystallization of the commercial Myozyme<sup>Â®</sup> precursor form of rhGAA (Q57-C952) did not afford crystals diffracting beyond ~7âÃ and protein disorder predictors<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> indicated the presence of disordered peptide regions, we performed in situ proteolysis with Î±-chymotrypsin to remove putative flexible surface loops hampering formation of productive crystal contacts. The proteolytic treatment yielded a polypeptide of ~5âkDa lower mass than the rhGAA precursor (Fig.Â <xref rid="Fig2" ref-type="fig">2a</xref>), which crystallized readily. This allowed us to collect the diffraction data extending to 1.9âÃ and solve the structure of rhGAA by molecular replacement (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). The proteolytically digested form had activity comparable to that of the precursor (2.34âÂ±â0.06 and 2.26âÂ±â0.16âUâmg<sup>â1</sup> for the precursor and mature forms, respectively), indicating that the Î±-chymotrypsin treatment did not alter the functionality of rhGAA.<fig id="Fig2"><label>Fig. 2</label><caption><p>Structure of mature rhGAA. <bold>a</bold> Proteolytic treatment of rhGAA. <bold>b</bold> Schematic representation of the sequence of GAA. Myozyme<sup>Â®</sup> rhGAA used in ERT starts at residue Q57. Domains corresponding to the rhGAA structure are colored as in <bold>c</bold>, with the regions removed by treatment with Î±-chymotrypsin colored in white. <bold>c</bold> Cartoon representation of the structure of rhGAA consisting of the trefoil type-P domain (salmon), the N-terminal Î²-sheet domain (slate), the catalytic GH31 (Î²/Î±)<sub>8</sub> barrel domain (green) with insert I (gold) and insert II (pink), and the proximal (orange) and distal (teal) Î²-sheet domains. Catalytic residues (magenta) and glycan chains (grey) are depicted as sticks. Dashed lined circles highlight peptide portions removed by proteolysis with Î±-chymotrypsin before crystallization. (SP, signal peptide; PP, propeptide)</p></caption><graphic xlink:href="41467_2017_1263_Fig2_HTML" id="d29e452"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Data collection and refinement statistics (molecular replacement)<sup>a, b</sup>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>rhGAA</th><th>rhGAA-NAC</th><th>rhGAA-DNJ</th><th>rhGAA-NHE-DNJ</th><th>rhGAA-acarbose</th></tr></thead><tbody><tr><td colspan="6">
<italic>Data collection</italic>
</td></tr><tr><td>Â Space group</td><td>
<italic>P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>
</td><td>
<italic>P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>
</td><td>
<italic>P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>
</td><td>
<italic>P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>
</td><td>
<italic>P</italic>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>
</td></tr><tr><td colspan="6">Cell dimensions</td></tr><tr><td>Â <italic>a, b, c</italic> (Ã)</td><td>98,102,129</td><td>97,102,129</td><td>97,103,129</td><td>97,102,128</td><td>97,103,128</td></tr><tr><td>Â Resolution (Ã)</td><td>48.83â1.90</td><td>47.62â1.83</td><td>53.80â2.00</td><td>47.47â2.00</td><td>51.49â2.45</td></tr><tr><td/><td>(1.93â1.90)</td><td>(1.86â1.83)</td><td>(2.04â2.00)</td><td>(2.04â2.00)</td><td>(2.54â2.45)</td></tr><tr><td>Â R<sub>merge</sub>
</td><td>0.103 (1.711)</td><td>0.072 (0.569)</td><td>0.159 (0.549)</td><td>0.134 (0.602)</td><td>0.188 (0.885)</td></tr><tr><td>Â R<sub>pim</sub>
</td><td>0.050 (0.823)</td><td>0.040 (0.311)</td><td>0.125 (0.426)</td><td>0.091 (0.421)</td><td>0.116 (0.554)</td></tr><tr><td>Â CC (1/2)</td><td>0.992 (0.661)</td><td>0.999 (0.859)</td><td>0.965 (0.675)</td><td>0.992 (0.722)</td><td>0.986 (0.644)</td></tr><tr><td>Â <italic>I</italic>/<italic>ÏI</italic>
</td><td>13.7 (1.2)</td><td>17.8 (3.3)</td><td>6.2 (2.0)</td><td>8.4 (2.3)</td><td>8.0 (1.9)</td></tr><tr><td>Â Completeness (%)</td><td>100 (100)</td><td>99.6 (92.0)</td><td>95.3 (95.5)</td><td>99.5 (100)</td><td>94.7 (97.0)</td></tr><tr><td>Â Redundancy</td><td>9.0 (9.2)</td><td>7.5 (7.1)</td><td>3.1 (3.0)</td><td>4.5 (4.2)</td><td>5.3 (5.2)</td></tr><tr><td>Â Wilson B (Ã<sup>2</sup>)</td><td>28.51</td><td>21.25</td><td>14.22</td><td>16.73</td><td>25.97</td></tr><tr><td colspan="6">
<italic>Refinement</italic>
</td></tr><tr><td>Â Resolution (Ã)</td><td>48.83â1.90</td><td>47.62â1.83</td><td>53.80â2.00</td><td>47.47â2.00</td><td>51.49â2.45</td></tr><tr><td>Â No. reflections</td><td>97,044</td><td>107,574</td><td>79,052</td><td>81,565</td><td>42,513</td></tr><tr><td>Â R<sub>work</sub>
</td><td>16.19 (33.0)</td><td>15.37 (23.60)</td><td>18.34 (22.70)</td><td>15.26 (21.30)</td><td>17.42 (26.0)</td></tr><tr><td>Â R<sub>free</sub>
</td><td>18.87 (33.80)</td><td>17.83 (26.00)</td><td>21.81 (27.40)</td><td>18.38 (24.60)</td><td>21.23 (30.20)</td></tr><tr><td colspan="6">No. atoms</td></tr><tr><td>Â Protein</td><td>6652</td><td>6669</td><td>6657</td><td>6653</td><td>6650</td></tr><tr><td>Â Ligand/ion</td><td>272</td><td>329</td><td>256</td><td>303</td><td>339</td></tr><tr><td>Â Water</td><td>668</td><td>776</td><td>773</td><td>633</td><td>290</td></tr><tr><td colspan="6">B-factors (Ã<sup>2</sup>)</td></tr><tr><td>Â Protein</td><td>31.46</td><td>24.01</td><td>17.81</td><td>20.74</td><td>28.87</td></tr><tr><td>Â Ligand/ion</td><td>59.56</td><td>56.20</td><td>49.34</td><td>43.67</td><td>54.76</td></tr><tr><td>Â Water</td><td>38.83</td><td>34.38</td><td>27.34</td><td>30.58</td><td>28.29</td></tr><tr><td colspan="6">R.m.s. deviations</td></tr><tr><td>Â Bond lengths (Ã)</td><td>0.009</td><td>0.008</td><td>0.009</td><td>0.007</td><td>0.007</td></tr><tr><td>Â Bond angles (Â°)</td><td>1.407</td><td>1.327</td><td>1.366</td><td>1.297</td><td>1.346</td></tr><tr><td colspan="6">Ramachandran</td></tr><tr><td>Â Favored (%)</td><td>97.96</td><td>97.74</td><td>97.72</td><td>97.24</td><td>97.74</td></tr><tr><td>Â Allowed (%)</td><td>2.04</td><td>2.14</td><td>2.28</td><td>2.64</td><td>2.14</td></tr><tr><td>Â Disallowed (%)</td><td>0</td><td>0.12</td><td>0</td><td>0.12</td><td>0.12</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>One single crystal was used for each data collection</p><p>
<sup>b</sup>Values in parentheses are for the highest-resolution shell</p></table-wrap-foot></table-wrap>
</p>
        <p id="Par6">The crystal structure of rhGAA corresponds to the mature form of human placental GAA and rhGAA<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> (Fig.Â <xref rid="Fig2" ref-type="fig">2b</xref>), suggesting that treatment with Î±-chymotrypsin afforded removal of protease-labile regions (Q57-T80, G116-M122, R199-A204 and A782-R794) in a manner comparable to the proteolytic maturation occurring in vivo. The overall architecture of rhGAA is similar to that of the human glycoside hydrolase family GH31<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> homologues, the intestinal brush-border enzymes maltase-glucoamylase (MGAM)<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup> and sucrase-isomaltase (SI)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> (Fig.Â <xref rid="Fig2" ref-type="fig">2c</xref> and Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">1</xref>). A N-terminal trefoil Type-P domain is followed by a Î²-sheet domain, the catalytic (Î²/Î±)<sub>8</sub> barrel bearing two inserts after Î²-strands Î²3 (insert I) and Î²4 (insert II), and proximal and distal Î²-sheet domains at the C-terminus. The precursor form of rhGAA contains ~14âkDa of carbohydrate and seven glycosylation sites have been predicted and characterized<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. We observed glycan structures of various lengths for five of them in the crystal structure, notably at N140, N233, N390, N470 and N652 (Fig.Â <xref rid="Fig2" ref-type="fig">2c</xref> and Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">2</xref>). We detected residual difference electron density at N882, insufficient to model a glycan structure, and did not observe difference electron density near N925.</p>
      </sec>
      <sec id="Sec4">
        <title>Active site and inhibitor binding</title>
        <p id="Par7">The narrow substrate-binding pocket of rhGAA is located near the C-terminal ends of Î²-strands of the catalytic (Î²/Î±)<sub>8</sub> domain and shaped by a loop from the N-terminal Î²-sheet domain and both inserts I and II (Fig.Â <xref rid="Fig2" ref-type="fig">2c</xref>). Family GH31 enzymes perform catalysis via a classical Koshland double displacement reaction mechanism with retention of the anomeric carbon configuration in the product. From early characterization of the catalytic site of GAA<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> and by homology with mechanistically dissected members of family GH31<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>, the catalytic nucleophile and acid/base can be assigned to D518 and D616, respectively. To get insight into the interaction of rhGAA with the documented pharmacological chaperone 1-deoxynojirimycin<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup> and its derivative N-hydroxyethyl-deoxynojirimycin<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> (DNJ and NHE-DNJ, respectively), we soaked rhGAA crystals with these active site directed iminosugar inhibitors and obtained for both complexes diffraction data extending to 2.0âÃ resolution (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). DNJ binds in a <sup>4</sup>C<sub>1</sub> conformation in the substrate-binding subsite â1<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> and is stabilized by hydrogen bonds to the side-chains of D404, D518, R600, D616, and H674. Further stabilizing interactions are provided by hydrophobic contacts with W376, I441, W516, M519, W613, and F649 (Fig.Â <xref rid="Fig3" ref-type="fig">3a, b</xref>). Apart from a 20Â° tilt in the side-chain of W376, no major conformational changes occur upon DNJ binding in the rhGAA active site. This is not the case for binding of NHE-DNJ, which adopts the same pose as DNJ, but where the hydroxyethyl substituent induces substantial conformational changes to the side chains of M519 and W481 (Fig.Â <xref rid="Fig3" ref-type="fig">3c, d</xref>). In this ligand-induced conformation, rhGAA residue W481, located on the tip of insert I, establishes a stabilizing interaction with the hydroxyethyl substituent of NHE-DNJ. Similar conformational changes can be observed upon binding of NHE-DNJ to the N-terminal subunit of MGAM (NtMGAM)<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">3a</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Ligand binding to rhGAA. DNJ (<bold>a</bold>), NHE-DNJ (<bold>c</bold>) and acarbose (<bold>e</bold>) colored in orange bound to rhGAA, color-coded as in Fig.Â <xref rid="Fig2" ref-type="fig">2c</xref>, overlapped onto unbound rhGAA (grey) in (<bold>a</bold>) and (<bold>c</bold>). Hydrogen bonding interactions are represented as dashed lines. In <bold>e</bold>, substrate-binding subsites are numbered and residues of a symmetry-related molecule are depicted in white sticks. Unbiased <italic>F</italic>
<sub><italic>o</italic></sub>
<italic>âF</italic>
<sub><italic>c</italic></sub> difference electron density maps, calculated before incorporation of the ligands into the models and contored at 3.0 Ï, are shown in <bold>b</bold>, <bold>d</bold> and <bold>f</bold>
</p></caption><graphic xlink:href="41467_2017_1263_Fig3_HTML" id="d29e1276"/></fig>
</p>
      </sec>
      <sec id="Sec5">
        <title>Substrate recognition and specificity</title>
        <p id="Par8">To gather a perception of substrate recognition by rhGAA, we acquired the diffraction data extending to 2.45âÃ resolution for a rhGAA crystal soaked with acarbose, a non-cleavable Î±â1,4-tetrasaccharide substrate analogue (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). In this complex, the valienamine ring lodged in subsite â1 adopts a <sup>2</sup>H<sub>3</sub> half-chair conformation, but despite this conformational difference with respect to DNJ bound in the <sup>4</sup>C<sub>1</sub> half-chair conformation, the hydrogen-bonding pattern in subsite â1 is essentially identical for the two compounds (Fig.Â <xref rid="Fig3" ref-type="fig">3e</xref>, f and Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">3b</xref>). The non-hydrolysable âinterglycosidicâ nitrogen occupies the catalytic centre and is hydrogen bonded to the catalytic acid/base D616. The 6-deoxyglucosyl moiety in subsiteâ+â1 establishes via its 2- and 3-hydroxyl groups hydrogen bonds with the conserved R600 and with D282 originating from a loop in the N-terminal Î²-sheet domain. Though not conserved in sequence, residues of this loop interact invariably with carbohydrate ligands in all the available crystal structures of family GH31 members. The maltose unit of acarbose in subsitesâ+â2 andâ+â3 does not make any direct interactions with rhGAA and is rather stabilized by crystal lattice packing interactions and a water mediated contact with the side chain of W618, located at the rim of the substrate-binding pocket. This paucity of interactions suggests that rhGAA possesses only two productive substrate-binding sites, subsites â1 andâ+â1, but interestingly, the acarbose maltose moiety bound to rhGAA adopts the same overall pose as when bound to NtMGAM<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> suggesting a functional role also for subsitesâ+â2 andâ+â3 in rhGAA (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">3c</xref>).</p>
        <p id="Par9">Glycogen is a large polymer build-up by linear chains of Î±â1,4-linked glucose residues carrying Î±-1,6-linked branches. In the cytosol the energy storage particle is degraded by the concomitant action of glycogen phosphorylase and a debranching enzyme. Within the lysosome, no debranching enzyme is present and GAA must assure the hydrolysis of both Î±-1,4- and Î±-1,6-glycosidic linkages. However, rhGAA shows clear preference for the former linkage, as the specificity constant on maltose is 32-fold higher when compared to the specificity constant on isomaltose (Supplementary TableÂ <xref rid="MOESM1" ref-type="media">2</xref>). To uncover the structural basis for the dual substrate specificity, we attempted soaking of rhGAA crystals with the non-hydrolysable tetrasaccharide glucopyranosyl-Î±-(1,6)-thio-maltotriose. However, this approach failed, most likely due to crystal contacts impeding accommodation of the tetrasaccharide, which by virtue of the Î±-1,6-linkage is slightly longer than acarbose. The latter has been observed to barely fit into the substrate-binding cleft and closely abut a symmetry related molecule (Fig.Â <xref rid="Fig3" ref-type="fig">3e</xref>). We derived an Î±-1,6-linked disaccharide bound within the active site of rhGAA by a structural superposition of rhGAA with the catalytic (Î²/Î±)<sub>8</sub> domain of <italic>Blautia obeum</italic> GAA in complex with isomaltose<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> (rmsd of 1.50âÃ for 318 aligned CÎ± positions). The model reveals that no steric hindrance occurs by the accommodation of a Î±-1,6-linkage between subsite â1 andâ+â1 and that productive hydrogen bonds between the glycopyranose moiety in subsiteâ+â1 and D282 are maintained (Fig.Â <xref rid="Fig4" ref-type="fig">4a, b</xref>). However, due to the increased length of the Î±-1,6-linkage with respect to an Î±-1,4-linkage, the stabilizing hydrogen bond with R600 is weakened, which might explain lower activity of the enzyme on Î±-1,6-linked branches.<fig id="Fig4"><label>Fig. 4</label><caption><p>rhGAA substrate recognition and specificity and allosteric chaperone binding sites. <bold>a</bold> Model of isomaltose (steelblue), derived from an overlap with <italic>B. obeum</italic> Î±-glucosidase in complex with isomaltose (PDB ID 3MKK), superposed onto the rhGAA-acarbose complex (rmsd of 1.50âÃ for 318 aligned CÎ± positions). <bold>b</bold> Model of isomaltose bound to rhGAA in surface representation. <bold>c</bold> The secondary substrate-binding site of rhGAA with unbiased <italic>F</italic>
<sub>o</sub>
<italic>âF</italic>
<sub>c</sub> difference electron density map calculated before incorporation of acarvosine (orange) into the model and contoured at 2.0 (lightblue) and 3.0 (blue) Ï. The surface loop removed by proteolytic treatment is represented by dashed lines. <bold>d</bold> NAC1 (orange) in the fully occupied binding site. <bold>e</bold> NAC2 (orange) in the partially occupied binding site. In <bold>d</bold> and <bold>e</bold>, unbiased <italic>F</italic>
<sub>o</sub>
<italic>âF</italic>
<sub>c</sub> difference electron density maps, calculated before incorporation of NAC into the model, are shown in lightblue (2.0 Ï) and blue (3.0 Ï)</p></caption><graphic xlink:href="41467_2017_1263_Fig4_HTML" id="d29e1392"/></fig>
</p>
      </sec>
      <sec id="Sec6">
        <title>The secondary substrate-binding domain</title>
        <p id="Par10">In the rhGAA-acarbose complex, we could observe the acarvosine moiety of a second acarbose molecule lodged in a pocket within the N-terminal trefoil Type-P domain, situated on the same face of rhGAA where the active site is located and 25âÃ away from acarbose bound therein (Fig.Â <xref rid="Fig4" ref-type="fig">4c</xref>). The valienamine moiety hydrogen-bonds with its 4- and 6-hydroxyl groups to the main-chain nitrogen and oxygen of C127, the main-chain oxygen of A93 and the side-chain of D91. Further stabilizing interactions are provided by stacking interactions with P125 and W126. P125 and D91 are conserved or replaced by conservative substitutions in the family GH31 enzymes comprising a trefoil Type-P domain (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">4a</xref>). Adjacent to the secondary carbohydrate-binding site the surface loop G116-M122 had been trimmed by proteolytic treatment. Conceivably, the removal of the segment G116-M122, unique to the lysosomal representatives of family GH31 (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">4a, b</xref>), might contribute to the formation of the secondary substrate-binding pocket. One could envisage that the secondary acarbose-binding site on rhGAA represents a genuine substrate-binding site possibly enhancing the processivity of the enzyme. This site could also represent a pharmacophore for in silico screening for novel pharmacological chaperones. Most notably, a trisaccharide derived from acarbose is bound to the N-terminal domain of family GH31 Î±-1,4-glucan lyase from <italic>Gracilariopsis lemaneiformis</italic>
<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> in a position close to the secondary substrate-binding site described here (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">5</xref>).</p>
      </sec>
      <sec id="Sec7">
        <title>N-acetylcysteine is an allosteric pharmacological chaperone</title>
        <p id="Par11">The known pharmaceutical drug N-acetylcysteine (NAC) has been shown to act as allosteric pharmacological chaperone enhancing the stability of mutated endogenous GAA and rhGAA used for ERT, without affecting the catalytic activity<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. To harness the therapeutic potential of NAC for Pompe disease via structural studies, we pursued the crystal structure of rhGAA in complex with NAC. The 1.83âÃ resolution structure of the complex obtained by crystal soaking experiments (TableÂ <xref rid="Tab1" ref-type="table">1</xref>), reveals two NAC-binding sites remote from the active site (Fig.Â <xref rid="Fig4" ref-type="fig">4d, e</xref>), providing structural evidence that NAC is indeed an allosteric chaperone, as anticipated by functional studies<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. We ascertained via activity assays and differential scanning fluorimetry that NAC stabilizes equally well rhGAA and the proteolytically matured enzyme produced in this study, and that the chaperone is specific towards GAA, as NAC has no stabilizing effect on a GH31 homologue from rice (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">6a, b</xref> and Supplementary TablesÂ <xref rid="MOESM1" ref-type="media">3</xref> and <xref rid="MOESM1" ref-type="media">4</xref>). In the rhGAA-NAC complex structure a NAC molecule, designated as NAC1, is located about 30âÃ away from the active site, at the interface between the (Î²/Î±)<sub>8</sub> barrel and the distal Î²-sheet domain (Fig.Â <xref rid="Fig4" ref-type="fig">4d</xref>). NAC1 binds to the main chain carboxyl of H432 via its amide nitrogen and the carboxyl function makes a water mediated contact with the side chain of D513. The CÎ²-SÎ³ and the acetyl groups establish stacking interactions with the guanidine group of R437 and the loop G434-G435, respectively. A second, partially (75%) occupied NAC molecule (NAC2), is lodged at the interface between the (Î²/Î±)<sub>8</sub> barrel and the proximal Î²-sheet domain at a distance of 25âÃ from the active site (Fig.Â <xref rid="Fig4" ref-type="fig">4e</xref>). The carboxyl function of NAC2 makes a water-mediated contact with the main-chain oxygen of L756, the thiol stacks against the side chain of Q757 and the acetyl group stacks against the side chain of H742. The two NAC molecules establish fewer and weaker interactions with rhGAA than the chaperones DNJ and NHE-DNJ. This reflects the higher concentrations of NAC needed for chaperone activity (mM vs, ÂµM) as exemplified by the <italic>K</italic>
<sub>D</sub> of 11.57Â±0.74âmM that we obtained by differential scanning fluorimetry and by the <italic>K</italic>
<sub><italic>i</italic></sub> of 3.4 and 3.0âÂµM for DNJ and NHE-DNJ, respectively<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. A sigmoidal saturation curve best fitting the experimental points supports the NAC allosteric fully (NAC1) and partially (NAC2) occupied binding sites (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">6c</xref>). The stacking interactions established between the acetyl groups of NAC1 and NAC2 and rhGAA must contribute significantly to the binding energy, since amino acids related to NAC, such as N-acetylserine and N-acetylglycine have equally a stabilizing effect on rhGAA, whilst the non-acetylated counterparts have no effect<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. The structure of the rhGAA-NAC complex shows a decrease in atomic thermal displacement parameters of residues surrounding the NAC-binding sites with respect to that of unbound rhGAA, pointing toward an overall inter-domain stabilizing function driven by NAC (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">7aâd</xref>). In the crystal NAC appears also to exercise an anti-oxidative effect as residue C938 is oxidized to the sulfenic acid form in all the crystal structures described here, except for the structure of the rhGAA-NAC complex (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">8a, b</xref>).</p>
      </sec>
      <sec id="Sec8">
        <title>NAC and iminosugars show different chaperoning profiles</title>
        <p id="Par12">Some mutations leading to Pompe disease are responsive to both NAC and the iminosugars DNJ and NB-DNJ, while others are targeted specifically by one or the other pharmacological chaperone<sup><xref ref-type="bibr" rid="CR16">16</xref>â<xref ref-type="bibr" rid="CR18">18</xref></sup>. The vast majority of GAA mutants responsive to the chaperone activity of iminosugars are located either in reach of the active site or on structural elements contributing to its global architecture. In Pompe patient, fibroblasts and mouse models the GAA mutants most responsive to NAC (A445P, Y455F, and L552P)<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> are located on inserts I and II, where the corresponding wild-type residues contribute to domain stabilizations. A445 together with F487 defines the boundaries of insert I, and the A445P mutant most likely destabilizes the entire scaffold of insert I (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">9a</xref>). The side-chain hydroxyl of Y455 on insert I interacts with a long loop of the catalytic domain whilst the side chain of L552 on insert II makes hydrophobic interactions with residues from the N-terminal Î²-sheet domain (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">9b, c</xref>). The respective Y455F and L552P mutants have most certainly an overall destabilizing effect, which is clearly rescued by NAC. Hence, the chaperone action of iminosugars can be considered as a conformational rescue of structural perturbed active sites, whereas the effect of the allosteric chaperone NAC appears to be due to the stabilization of overall or local conformational fluctuations.</p>
      </sec>
    </sec>
    <sec id="Sec9" sec-type="discussion">
      <title>Discussion</title>
      <p id="Par13">Although lysosomal storage diseases have low incidence in overall population, they represent a heavy burden to patientsâ health and have an important socio-economic impact. ERT with recombinant human rhGAA has become available as drug for the standard care for Pompe disease a decade ago and has proven to be beneficial for patientâs survival and to stabilize the disease course<sup><xref ref-type="bibr" rid="CR5">5</xref>â<xref ref-type="bibr" rid="CR8">8</xref></sup>. Undoubtedly, structural information was desired to harness the therapeutic value of rhGAA, but remarkably, this live-saving drug could not be crystallized so far and its 3D-structure remained elusive. Yet, shortly after submission of this manuscript the Garman group released two isomorphous structures of recombinantly expressed human GAA in complex with glucose at the Protein Data Bank, with accession numbers 5KZW and 5KZX.</p>
      <p id="Par14">In this study we employed in situ proteolysis to afford well-diffracting crystals of rhGAA and interestingly the crystallographic model we obtained corresponds to the mature forms of recombinant and placental GAA found in the endosome/lysosomal compartment<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. One of the peptide segments removed by proteolytic treatment (G116-M122) is specific to the lysosmal representatives of the GH31 enzyme family and its removal might be required for the generation of the secondary substrate-binding site in the trefoil Type-P domain. De facto, none of the over a dozen native or complex structures of the human intestinal homologues MGAM and SI, where the peptide range corresponding to rhGAA G116-M122 is present, contains a carbohydrate or carbohydrate-like ligand such as glycerol in the area corresponding to the rhGAA secondary substrate-binding site. The secondary substrate-binding site might favor the adherence of the enzyme onto the glycogen particle during hydrolytic processing and enhance its ability to detangle the Î±-1,6-linked branch points, which in cytosolic glycogen metabolism are taken care of by a debranching enzyme, not present in the lysosome. Except for the human intestinal homologues, the other structurally characterized GH31 members do not contain a trefoil Type-P domain, but interestingly a secondary substrate-binding site is equally present in the N-terminal region of <italic>G. lemaneiformis</italic> Î±-1,4-glucan lyase, which degrades starch following an elimination mechanism instead of hydrolysis. With an increasing amount of forthcoming structural and functional data it should be interesting to see whether within glycoside hydrolase family GH31 relationships can be established between particular modes of substrate binding and degradation.</p>
      <p id="Par15">Despite the clinical benefits of ERT with rhGAA, patientâs response is very variable and mostly limited by insufficient enzyme targeting to the lysosomal compartment, high cost and heavy burden of treatment. In recent years PCT, presenting advantages such as low cost and burden, and high distribution volume, has emerged as an attractive alternative, either alone or in combination with ERT, for the treatment of LSDs<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>. For Pompe disease, for which clinical trials combining ERT and treatment with NB-DNJ and DNJ have recently been concluded<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>, PCT is particularly promising as pharmacological chaperones are small molecules that are expected to penetrate membranes and reach therapeutic levels in target tissues, including skeletal muscle (38â55% of human body weight), more easily than rhGAA. A potential drawback of most pharmacological chaperones under study for the rescue of lysosomal glycosidases is that they are active site-directed iminosugars and inhibitors of the target enzymes. Furthermore, glucose configured iminosugars targeting GAA have the additional drawback of inhibiting also the intestinal starch-digesting enzymes and the endoplasmic reticulum glycoprotein processing enzyme GAA II. The identification of second-generation chaperones able to stabilize target enzymes without inhibitory action and undesired off-target effects is thus highly desirable. In this study, we were able to harness by structural and biochemical analyses the therapeutic value of the previously identified pharmacological chaperone NAC. On the basis of docking studies using a structural model of GAA derived from the X-ray structure of NtMGAM, the authors of the original report on the allosteric chaperoning function of NAC<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> proposed a NAC-binding site at the interface between the catalytic (Î²/Î±)<sub>8</sub> barrel and the distal Î²-sheet domain of GAA. Although located in proximity of the observed NAC1 binding site, this âvirtualâ pocket derived from a homology-based model is not present in the experimental 3D structure of rhGAA, emphasizing that homology models can provide guidance to virtual screening up to a certain extent, but ultimately experimental data are needed for precise mapping of binding sites. Interestingly, an astonishingly high number of small solvent molecules originating from the crystallization medium (glycerol, ethylene glycol, sulphate, chloride) are present in the different rhGAA structures presented here. Based on the principle of the multiple solvent crystal structures approach<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, the different ligand binding sites might provide guidance to pharmacophore mapping in high-throughput screening experiments devoted to the identification of novel allosteric chaperones. We envisage that the structural framework provided here will allow mapping of disease mutations and guide clinicians in therapeutic choices and furthermore supply an accurate molecular scaffold for in silico screening to map novel druggable sites and identify novel pharmacological chaperones with complementary and synergistic effect on adverse GAA mutations.</p>
    </sec>
    <sec id="Sec10" sec-type="materials|methods">
      <title>Methods</title>
      <sec id="Sec11">
        <title>Sample preparation</title>
        <p id="Par16">rhGAA (algucosidase alfa, Myozyme<sup>Â®</sup>) produced in CHO cells in the precursor form was from Genzyme, Cambridge, MA. As source of enzyme, the residual amounts of the infusions of Myozyme<sup>Â®</sup> administrated for the treatment of Pompe patients at the Department of Translational Medical Sciences, Federico II University, Naples, Italy, were used. For the infusions, Myozyme<sup>Â®</sup> was conditioned in a buffer composed of 110âmM mannitol, 36âÎ¼M polysorbate 80 (Tween80), 3âmM Na<sub>2</sub>HPO<sub>4</sub>â¢7H<sub>2</sub>O and 21âmM NaH<sub>2</sub>PO<sub>4</sub>â¢H<sub>2</sub>O, pH 6.1. One aliquot of the infusion residuals was dialyzed against a buffer composed of 10âmM HEPES pH 7.0 and 150âmM NaCl, whereas a second aliquot was dialyzed against 10âmM Na-citrate buffer pH 5.5, supplemented with 150âmM NaCl. Extensive crystallization trials with rhGAA in the original buffer and in the HEPES and citrate buffer conditions provided crystals diffracting at the best to about 7âÃ resolution. Protein disorder prediction with the computational tool DisEMBL<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> (<ext-link ext-link-type="uri" xlink:href="http://dis.embl.de/">http://dis.embl.de/</ext-link>) indicated the existence of disordered regions within the rhGAA sequence and limited proteolysis was thus envisaged to remove potential disordered surface loops deleterious for the formation of well-ordered crystals. To this aim, rhGAA was dialyzed against a buffer composed of 10âmM HEPES pH 7.6, 200âmM NaCl and 2âmM CaCl<sub>2</sub> and Î±-chymotrypsin and subtilysin were tested at different protease to protein mass ratios ranging from 1:2 to 1:100, at different incubation times and incubation temperatures. At selected time points, aliquots were removed from the reaction mixture and analysed by SDS-PAGE. Best and reproducible results were obtained by Î±-chymotrypsin treatment overnight at 20âÂ°C and with a protease/rhGAA mass ratio of 1:2, affording a band on SDS-PAGE (8%) with a mass difference of ~5âkDa with respect to the rhGAA precursor (Fig.Â <xref rid="Fig2" ref-type="fig">2a</xref>). The proteolysed enzyme was separated from the proteolytic reaction mixture by size-exclusion chromatography in 10âmM HEPES pH 7.0 and 100âmM NaCl using a HiLoad 16/60 Superdex 200 column, and concentrated to approximately 3.7âmgâml<sup>â1</sup> using a centrifugal filter unit with a 30-kDa cutoff. N-terminal sequencing of proteolysed rhGAA was performed using a PROCISE<sup>Â®</sup> 494 sequencing system.</p>
      </sec>
      <sec id="Sec12">
        <title>Activity tests on the rhGAA forms</title>
        <p id="Par17">The activity assays were performed at 37âÂ°C by adding 5âÂµg of precursor or mature forms of rhGAA to 0.2âml of reaction mixture containing 20âmM 4NP-Glc and 100âmM Na-acetate pH 4.0. After 2âmin the reactions were blocked by adding 0.8âml of 1âM Na-carbonate pH 10.2. Absorbance was measured at 420ânm at room temperature and the extinction coefficient to calculate enzymatic units was 17.2âmM<sup>â1</sup>âcm<sup>â1</sup>. One enzymatic unit is defined as the amount of enzyme catalyzing the conversion of 1âÎ¼mol substrate into product in 1âmin, under the indicated conditions. Spontaneous hydrolysis of the substrates was subtracted by using appropriate blank mixtures without enzyme. All the kinetic data were calculated as the average of at least two experiments and were plotted and refined with the program Prism 5.0 (GraphPad Software, San Diego, CA USA).</p>
      </sec>
      <sec id="Sec13">
        <title>Crystallization and structure solution</title>
        <p id="Par18">Crystallization trials were performed by the sitting-drop vapour-diffusion method using a Mosquito<sup>Â®</sup> (TTP labtech) crystallization robot and commercial screens. First crystal hits emerged from a condition of the Structure Screen 1 (Molecular Dimensions) containing 2.0âM ammonium sulphate, 0.1âM HEPES pH 7.5 and 2% v/v PEG400, and after several optimization rounds well diffracting crystals were obtained by the hanging-drop vapour-diffusion method by mixing 1âÂµl protein solution at 3.7âmgâml<sup>â1</sup> with 0.5âÂµl reservoir solution composed of 1.9âM ammonium sulfate, 0.1âM HEPES pH 7.0 and 2% v/v PEG400. Crystals belong to space group P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> with average unit cell axes of 97âÃâ103âÃâ128âÃ and one molecule per asymmetric unit. Ligand soaking was performed by the addition of small amounts of powder of NAC, DNJ, NHE-DNJ or acarbose to the crystallization droplets (1â2 snowflake-like crystals of approximate dimensions of 0.5âmm), followed by incubation for ~1âh. Native rhGAA crystals were flash-cooled directly in liquid nitrogen, whereas crystals soaked with the various ligands were cryo-protected with reservoir solution supplemented with 15% (v/v) glycerol prior cooling. X-ray diffraction data were acquired at beam line Proxima1 at the Synchrotron Soleil, Gif-sur-Yvette, and at beam line ID23-2 at the European Synchrotron Radiation Facility, Grenoble. All diffraction data were processed with XDS<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> and scaled and merged using the CCP4<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> suite of programs Pointless, Aimless<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> and Truncate.</p>
        <p id="Par19">The structure of rhGAA was solved by molecular replacement with the program Phaser<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> using the coordinates of <italic>Homo sapiens</italic> NtMGAM (PDB ID 2QLY, 44% sequence identity with GAA) as search model (rotation function Z-score: 7.0; translation function Z-score: 21.4; number of clashes from packing analysis: 0; log likelihood gain: 1383). Subsequent auto-building with the program Buccaneer<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> yielded a model that was 93% complete with <italic>R</italic>
<sub>free</sub> of 31.2%. Maximum-likelihood refinement, including TLS, and model adjustment were carried out with the programs Refmac<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> and Coot<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>, respectively. Random sets of ~5% of reflections, depending on the resolution limit, were set aside for cross-validation purposes. The composition of cross-validation data sets was systematically taken over from the parent data set. Model quality was assessed with internal modules of Coot<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> and with the Molprobity server<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Ligands were fitted into unbiased <italic>F</italic>
<sub>o</sub>
<italic>âF</italic>
<sub>c</sub> difference electron density maps calculated after 10 cycles of rigid body refinement with Refmac<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. The data collection and refinement statistics are listed in TableÂ <xref rid="Tab1" ref-type="table">1</xref> with representative electron density in Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref> and Supplementary Figs.Â <xref rid="MOESM1" ref-type="media">2</xref> and <xref rid="MOESM1" ref-type="media">8</xref>. Figures representing structural renderings were generated with the PyMOL Molecular Graphics System (DeLano, W.L. The PyMOL Molecular Graphics on <ext-link ext-link-type="uri" xlink:href="http://www.pymol.org/">http://www.pymol.org/</ext-link>). Chemical structures were drawn with ChemDraw 9.0 Pro (Cambrigesoft Corp, Cambridge, MA). Sequence alignments were made using MUSCLE<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> and graphical rendering of the alignments, taking into account structural information, were made with ESPript<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>.</p>
      </sec>
      <sec id="Sec14">
        <title>Differential scanning fluorimetry</title>
        <p id="Par20">Thermal stability scans of rhGAA were performed as described in Porto et al., 2012<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Briefly, the enzyme was diluted 48-fold (0.1âmgâml<sup>â1</sup>) in 25âmM Na-phosphate buffer, pH 7.4, 150âmM NaCl and 1:1000 SYPRO Orange dye (Life Technologies). Thermal scans were performed in triplicate in absence or in presence of 10âmM NAC, with steps of 1âÂ°C min<sup>â1</sup> in the range 25â95âÂ°C in a Real Time LightCycler (Bio-Rad). Fluorescence was normalized to the maximum value within each scan to obtain relative fluorescence. Melting temperatures were calculated according to Niesen et al., 2007<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. The standard deviations for each melting temperature were calculated from three replicates.</p>
        <p id="Par21">The dissociation constant (<italic>K</italic>
<sub>D</sub>) of NAC was measured by thermal stability scans of rhGAA according to Vivoli et al., 2014<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. DSF scans were performed as described above, in the range 0â28âmM NAC. The melting temperature values were plotted as function of ligand concentration. The experimental data were best fitted according to a simple cooperative model equation reported in Vivoli et al., 2014<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> by using the software GraphPAD Prism (GraphPad Software, San Diego, CA, USA). To measure the thermal stability of GAA from rice type V (resuspended in 2.8âM ammonium sulphate) (Sigma-Aldrich), the enzyme was diluted 34.5-fold (0.1âmgâml<sup>â1</sup>) and the thermal scans were performed as described above for rhGAA.</p>
      </sec>
      <sec id="Sec15">
        <title>Kinetic constants of rhGAA on different substrates</title>
        <p id="Par22">All substrates were purchased from Sigma-Aldrich. Kinetic constants on 4NP-Glc (1â35âmM) were measured as described above. Kinetic constants on maltose (1â150âmM) and isomaltose (15â200âmM) were measured in 100âmM Na-acetate buffer pH 4.0 at 37âÂ°C, by using 5 and 15âÎ¼g of enzyme, in a final volume of 0.2 and 0.1âml, respectively. After 2âmin, the amount of glucose produced in the reactions was determined using a glucose oxidase-peroxidase system (<sc>D</sc>-Glucose kit, Megazyme). One unit of activity was defined as the amount of enzyme releasing 1âÎ¼mol of glucose per minute at the conditions described. Spontaneous hydrolysis of the substrates was subtracted by using appropriate blank mixtures without enzyme. All the kinetic data were calculated as the average of at least two experiments and were plotted and refined with the program Prism 5.0 (GraphPad Software, San Diego, CA, USA).</p>
        <p id="Par23">Kinetic constants on bovine and rabbit glycogens were measured by using the substrates ranging from 1 to 123âmgâml<sup>â1</sup> in 50âmM citrate-phosphate buffer pH 4.0 at 37âÂ°C by using 5âÎ¼g of enzyme in the final volume of 0.1âml. After 2âmin, 0.1âml of Naâcarbonate 0.25âM was added to the reaction mixtures. To determine the amount of reducing sugars released 0.1âml were analysed by the SomogyiâNelson assay<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. One unit of activity was defined as the amount of enzyme releasing 1âÎ¼mol of reducing equivalents per minute at the conditions described.</p>
      </sec>
      <sec id="Sec16">
        <title>Data availability</title>
        <p id="Par24">The atomic coordinates and structure factors of rhGAA and complexes with NAC, DNJ, NHE-DNJ and acarbose have been deposited in the Protein Data Bank with accession numbers 5NN3, 5NN4, 5NN5, 5NN6 and 5NN8, respectively. All the other data are available from the corresponding author on request.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec17">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41467_2017_1263_MOESM1_ESM.pdf"><caption><p>Supplementary information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41467_2017_1263_MOESM2_ESM.pdf"><caption><p>Peer Review file</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Electronic supplementary material</bold>
        </p>
        <p>
<bold>Supplementary Information</bold> accompanies this paper at doi:10.1038/s41467-017-01263-3.</p>
      </fn>
      <fn>
        <p>
<bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We are grateful to S. Cottaz for providing glucopyranosyl-Î±-(1,6)-thio-maltotriose. We thank the European Synchrotron Radiation Facility (ESRF) and Synchrotron Soleil for beam time allocation and the beam line staff for assistance with data collection. This work was supported in part by the CNRS and the French Infrastructure for Integrated Structural Biology (FRISBI) ANR-10-INSB-05â01. Telethon support to G.P. is gratefully acknowledged.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>V.R.-Z. and S.G.: Performed limited proteolysis, purification and crystallization. G.S. performed crystallographic studies. R.I. and M.C.F.: Performed enzymology and Differential scanning fluorimetry studies, B.C.-P., M.M. and G.S.: Designed the study. G.S.: Wrote the manuscript with valuable contributions from B.C.-P., Y.B., G.P. and M.M.</p>
    </notes>
    <notes notes-type="COI-statement">
      <sec id="FPar1">
        <title>Competing interests</title>
        <p id="Par25">The authors declare no competing financial interests.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lombard</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Golaconda Ramulu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Drula</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Coutinho</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Henrissat</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The carbohydrate-active enzymes database (CAZy) in 2013</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2014</year>
          <volume>42</volume>
          <fpage>D490</fpage>
          <lpage>D495</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gkt1178</pub-id>
          <?supplied-pmid 24270786?>
          <pub-id pub-id-type="pmid">24270786</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van der Ploeg</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Reuser</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Pompeâs disease</article-title>
          <source>Lancet</source>
          <year>2008</year>
          <volume>372</volume>
          <fpage>1342</fpage>
          <lpage>1353</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(08)61555-X</pub-id>
          <?supplied-pmid 18929906?>
          <pub-id pub-id-type="pmid">18929906</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raben</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Plotz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Byrne</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)</article-title>
          <source>Curr. Mol. Med.</source>
          <year>2002</year>
          <volume>2</volume>
          <fpage>145</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="doi">10.2174/1566524024605789</pub-id>
          <?supplied-pmid 11949932?>
          <pub-id pub-id-type="pmid">11949932</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parenti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Andria</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Pompe disease: from new views on pathophysiology to innovative therapeutic strategies</article-title>
          <source>Curr. Pharm. Biotechnol.</source>
          <year>2011</year>
          <volume>12</volume>
          <fpage>902</fpage>
          <lpage>915</lpage>
          <pub-id pub-id-type="doi">10.2174/138920111795542606</pub-id>
          <?supplied-pmid 21235442?>
          <pub-id pub-id-type="pmid">21235442</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van den Hout</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk</article-title>
          <source>Pediatrics</source>
          <year>2004</year>
          <volume>113</volume>
          <fpage>e448</fpage>
          <lpage>e457</lpage>
          <pub-id pub-id-type="doi">10.1542/peds.113.5.e448</pub-id>
          <?supplied-pmid 15121988?>
          <pub-id pub-id-type="pmid">15121988</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kishnani</surname>
              <given-names>PS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease</article-title>
          <source>J. Pediatr.</source>
          <year>2006</year>
          <volume>149</volume>
          <fpage>89</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpeds.2006.02.035</pub-id>
          <?supplied-pmid 16860134?>
          <pub-id pub-id-type="pmid">16860134</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>LR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease</article-title>
          <source>J. Pediatr.</source>
          <year>2009</year>
          <volume>155</volume>
          <fpage>271</fpage>
          <lpage>275.e2</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpeds.2009.03.015</pub-id>
          <?supplied-pmid 19486996?>
          <pub-id pub-id-type="pmid">19486996</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rossi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells</article-title>
          <source>J. Child. Neurol.</source>
          <year>2007</year>
          <volume>22</volume>
          <fpage>565</fpage>
          <lpage>573</lpage>
          <pub-id pub-id-type="doi">10.1177/0883073807302598</pub-id>
          <?supplied-pmid 17690063?>
          <pub-id pub-id-type="pmid">17690063</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van der Ploeg</surname>
              <given-names>AT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A randomized study of alglucosidase alfa in late-onset Pompeâs disease</article-title>
          <source>N. Engl. J. Med.</source>
          <year>2010</year>
          <volume>362</volume>
          <fpage>1396</fpage>
          <lpage>1406</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0909859</pub-id>
          <?supplied-pmid 20393176?>
          <pub-id pub-id-type="pmid">20393176</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardone</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts</article-title>
          <source>Pathogenetics</source>
          <year>2008</year>
          <volume>1</volume>
          <fpage>6</fpage>
          <pub-id pub-id-type="doi">10.1186/1755-8417-1-6</pub-id>
          <?supplied-pmid 19046416?>
          <pub-id pub-id-type="pmid">19046416</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kishnani</surname>
              <given-names>PS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants</article-title>
          <source>Mol. Genet. Metab.</source>
          <year>2010</year>
          <volume>99</volume>
          <fpage>26</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ymgme.2009.08.003</pub-id>
          <?supplied-pmid 19775921?>
          <pub-id pub-id-type="pmid">19775921</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fukuda</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease</article-title>
          <source>Mol. Ther.</source>
          <year>2006</year>
          <volume>14</volume>
          <fpage>831</fpage>
          <lpage>839</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ymthe.2006.08.009</pub-id>
          <?supplied-pmid 17008131?>
          <pub-id pub-id-type="pmid">17008131</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parenti</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics</article-title>
          <source>EMBO Mol. Med.</source>
          <year>2009</year>
          <volume>1</volume>
          <fpage>268</fpage>
          <lpage>279</lpage>
          <pub-id pub-id-type="doi">10.1002/emmm.200900036</pub-id>
          <?supplied-pmid 20049730?>
          <pub-id pub-id-type="pmid">20049730</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parenti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Andria</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Valenzano</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders</article-title>
          <source>Mol. Ther.</source>
          <year>2015</year>
          <volume>23</volume>
          <fpage>1138</fpage>
          <lpage>1148</lpage>
          <pub-id pub-id-type="doi">10.1038/mt.2015.62</pub-id>
          <?supplied-pmid 25881001?>
          <pub-id pub-id-type="pmid">25881001</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fan</surname>
              <given-names>JQ</given-names>
            </name>
          </person-group>
          <article-title>A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity</article-title>
          <source>Biol. Chem.</source>
          <year>2008</year>
          <volume>389</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1515/BC.2008.009</pub-id>
          <?supplied-pmid 18095864?>
          <pub-id pub-id-type="pmid">18095864</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flanagan</surname>
              <given-names>JJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase</article-title>
          <source>Hum. Mutat.</source>
          <year>2009</year>
          <volume>30</volume>
          <fpage>1683</fpage>
          <lpage>1692</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.21121</pub-id>
          <?supplied-pmid 19862843?>
          <pub-id pub-id-type="pmid">19862843</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Porto</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts</article-title>
          <source>Mol. Ther.</source>
          <year>2009</year>
          <volume>17</volume>
          <fpage>964</fpage>
          <lpage>971</lpage>
          <pub-id pub-id-type="doi">10.1038/mt.2009.53</pub-id>
          <?supplied-pmid 19293774?>
          <pub-id pub-id-type="pmid">19293774</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Porto</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pharmacological enhancement of Î±-glucosidase by the allosteric chaperone N-acetylcysteine</article-title>
          <source>Mol. Ther.</source>
          <year>2012</year>
          <volume>20</volume>
          <fpage>2201</fpage>
          <lpage>2211</lpage>
          <pub-id pub-id-type="doi">10.1038/mt.2012.152</pub-id>
          <?supplied-pmid 22990675?>
          <pub-id pub-id-type="pmid">22990675</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Hove</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Brady</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>YT</given-names>
            </name>
          </person-group>
          <article-title>High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease</article-title>
          <source>Proc. Natl Acad. Sci. USA</source>
          <year>1996</year>
          <volume>93</volume>
          <fpage>65</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.93.1.65</pub-id>
          <?supplied-pmid 8552676?>
          <pub-id pub-id-type="pmid">8552676</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreland</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor</article-title>
          <source>J. Biol. Chem.</source>
          <year>2005</year>
          <volume>280</volume>
          <fpage>6780</fpage>
          <lpage>6791</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M404008200</pub-id>
          <?supplied-pmid 15520017?>
          <pub-id pub-id-type="pmid">15520017</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linding</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protein disorder prediction: implications for structural proteomics</article-title>
          <source>Structure</source>
          <year>2003</year>
          <volume>11</volume>
          <fpage>1453</fpage>
          <lpage>1459</lpage>
          <pub-id pub-id-type="doi">10.1016/j.str.2003.10.002</pub-id>
          <?supplied-pmid 14604535?>
          <pub-id pub-id-type="pmid">14604535</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sim</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Quezada-Calvillo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sterchi</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Human intestinal maltase-glucoamylase: crystal structure of the N-terminal catalytic subunit and basis of inhibition and substrate specificity</article-title>
          <source>J. Mol. Biol.</source>
          <year>2008</year>
          <volume>375</volume>
          <fpage>782</fpage>
          <lpage>792</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jmb.2007.10.069</pub-id>
          <?supplied-pmid 18036614?>
          <pub-id pub-id-type="pmid">18036614</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ren</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structural insight into substrate specificity of human intestinal maltase-glucoamylase</article-title>
          <source>Protein Cell</source>
          <year>2011</year>
          <volume>2</volume>
          <fpage>827</fpage>
          <lpage>836</lpage>
          <pub-id pub-id-type="doi">10.1007/s13238-011-1105-3</pub-id>
          <?supplied-pmid 22058037?>
          <pub-id pub-id-type="pmid">22058037</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sim</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structural basis for substrate selectivity in human maltase-glucoamylase and sucrase-isomaltase N-terminal domains</article-title>
          <source>J. Biol. Chem.</source>
          <year>2010</year>
          <volume>285</volume>
          <fpage>17763</fpage>
          <lpage>17770</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M109.078980</pub-id>
          <?supplied-pmid 20356844?>
          <pub-id pub-id-type="pmid">20356844</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hermans</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Kroos</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>van Beeumen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Oostra</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Reuser</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Human lysosomal alpha-glucosidase. characterization of the catalytic site</article-title>
          <source>J. Biol. Chem.</source>
          <year>1991</year>
          <volume>266</volume>
          <fpage>13507</fpage>
          <lpage>13512</lpage>
          <?supplied-pmid 1856189?>
          <pub-id pub-id-type="pmid">1856189</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lovering</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YW</given-names>
            </name>
            <name>
              <surname>Withers</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Strynadka</surname>
              <given-names>NC</given-names>
            </name>
          </person-group>
          <article-title>Mechanistic and structural analysis of a family 31 alpha-glycosidase and its glycosyl-enzyme intermediate</article-title>
          <source>J. Biol. Chem.</source>
          <year>2005</year>
          <volume>280</volume>
          <fpage>2105</fpage>
          <lpage>2115</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M410468200</pub-id>
          <?supplied-pmid 15501829?>
          <pub-id pub-id-type="pmid">15501829</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>YW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expanding the thioglycoligase strategy to the synthesis of alpha-linked thioglycosides allows structural investigation of the parent enzyme/substrate complex</article-title>
          <source>J. Am. Chem. Soc.</source>
          <year>2006</year>
          <volume>128</volume>
          <fpage>2202</fpage>
          <lpage>2203</lpage>
          <pub-id pub-id-type="doi">10.1021/ja057904a</pub-id>
          <?supplied-pmid 16478160?>
          <pub-id pub-id-type="pmid">16478160</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kishnani</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Duvoglustat HCl increases systemic and tissue exposure of active acid Î±-glucosidase in pompe patients co-administered with alglucosidase Î±</article-title>
          <source>Mol. Ther.</source>
          <year>2017</year>
          <volume>25</volume>
          <fpage>1199</fpage>
          <lpage>1208</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ymthe.2017.02.017</pub-id>
          <?supplied-pmid 28341561?>
          <pub-id pub-id-type="pmid">28341561</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bruckmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Repo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kuokkanen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Xhaard</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Heikinheimo</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Systematic structure-activity study on potential chaperone lead compounds for acid Î±-glucosidase</article-title>
          <source>ChemMedChem.</source>
          <year>2012</year>
          <volume>7</volume>
          <fpage>1943</fpage>
          <lpage>1953</lpage>
          <pub-id pub-id-type="doi">10.1002/cmdc.201200309</pub-id>
          <?supplied-pmid 22969039?>
          <pub-id pub-id-type="pmid">22969039</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Henrissat</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Nomenclature for sugar-binding subsites in glycosyl hydrolases</article-title>
          <source>Biochem. J.</source>
          <year>1997</year>
          <volume>321</volume>
          <fpage>557</fpage>
          <pub-id pub-id-type="doi">10.1042/bj3210557</pub-id>
          <?supplied-pmid 9020895?>
          <pub-id pub-id-type="pmid">9020895</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sim</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>New glucosidase inhibitors from an ayurvedic herbal treatment for type 2 diabetes: structures and inhibition of human intestinal maltase-glucoamylase with compounds from Salacia reticulata</article-title>
          <source>Biochemistry</source>
          <year>2010</year>
          <volume>49</volume>
          <fpage>443</fpage>
          <lpage>451</lpage>
          <pub-id pub-id-type="doi">10.1021/bi9016457</pub-id>
          <?supplied-pmid 20039683?>
          <pub-id pub-id-type="pmid">20039683</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tan</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Novel Î±-glucosidase from human gut microbiome: substrate specificities and their switch</article-title>
          <source>FASEB J.</source>
          <year>2010</year>
          <volume>24</volume>
          <fpage>3939</fpage>
          <lpage>3949</lpage>
          <pub-id pub-id-type="doi">10.1096/fj.10-156257</pub-id>
          <?supplied-pmid 20581222?>
          <pub-id pub-id-type="pmid">20581222</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rozeboom</surname>
              <given-names>HJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Crystal structure of Î±â1,4-glucan lyase, a unique glycoside hydrolase family member with a novel catalytic mechanism</article-title>
          <source>J. Biol. Chem.</source>
          <year>2013</year>
          <volume>288</volume>
          <fpage>26764</fpage>
          <lpage>26774</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M113.485896</pub-id>
          <?supplied-pmid 23902768?>
          <pub-id pub-id-type="pmid">23902768</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parenti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Moracci</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fecarotta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Andria</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Pharmacological chaperone therapy for lysosomal storage diseases</article-title>
          <source>Future Med. Chem.</source>
          <year>2014</year>
          <volume>6</volume>
          <fpage>1031</fpage>
          <lpage>1045</lpage>
          <pub-id pub-id-type="doi">10.4155/fmc.14.40</pub-id>
          <?supplied-pmid 25068986?>
          <pub-id pub-id-type="pmid">25068986</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parenti</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A chaperone enhances blood Î±-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy</article-title>
          <source>Mol. Ther.</source>
          <year>2014</year>
          <volume>22</volume>
          <fpage>2004</fpage>
          <lpage>2012</lpage>
          <pub-id pub-id-type="doi">10.1038/mt.2014.138</pub-id>
          <?supplied-pmid 25052852?>
          <pub-id pub-id-type="pmid">25052852</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mattos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ringe</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Locating and characterizing binding sites on proteins</article-title>
          <source>Nat. Biotechnol.</source>
          <year>1996</year>
          <volume>14</volume>
          <fpage>595</fpage>
          <lpage>599</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt0596-595</pub-id>
          <?supplied-pmid 9630949?>
          <pub-id pub-id-type="pmid">9630949</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kabsch</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>XDS</article-title>
          <source>Acta. Crystallogr. D. Biol. Crystallogr.</source>
          <year>2010</year>
          <volume>66</volume>
          <fpage>125</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id>
          <?supplied-pmid 20124692?>
          <pub-id pub-id-type="pmid">20124692</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winn</surname>
              <given-names>MD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Overview of the CCP4 suite and current developments</article-title>
          <source>Acta. Crystallogr. D. Biol. Crystallogr.</source>
          <year>2011</year>
          <volume>67</volume>
          <fpage>235</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1107/S0907444910045749</pub-id>
          <?supplied-pmid 21460441?>
          <pub-id pub-id-type="pmid">21460441</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Murshudov</surname>
              <given-names>GN</given-names>
            </name>
          </person-group>
          <article-title>How good are my data and what is the resolution?</article-title>
          <source>Acta. Crystallogr. D Biol. Crystallogr.</source>
          <year>2013</year>
          <volume>69</volume>
          <fpage>1204</fpage>
          <lpage>1214</lpage>
          <pub-id pub-id-type="doi">10.1107/S0907444913000061</pub-id>
          <?supplied-pmid 23793146?>
          <pub-id pub-id-type="pmid">23793146</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCoy</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phaser crystallographic software</article-title>
          <source>J. Appl. Crystallogr.</source>
          <year>2007</year>
          <volume>40</volume>
          <fpage>658</fpage>
          <lpage>674</lpage>
          <pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id>
          <?supplied-pmid 19461840?>
          <pub-id pub-id-type="pmid">19461840</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cowtan</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>The Buccaneer software for automated model building. 1. Tracing protein chains</article-title>
          <source>Acta. Crystallogr. D Biol. Crystallogr.</source>
          <year>2006</year>
          <volume>62</volume>
          <fpage>1002</fpage>
          <lpage>1011</lpage>
          <pub-id pub-id-type="doi">10.1107/S0907444906022116</pub-id>
          <?supplied-pmid 16929101?>
          <pub-id pub-id-type="pmid">16929101</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murshudov</surname>
              <given-names>GN</given-names>
            </name>
            <name>
              <surname>Vagin</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Dodson</surname>
              <given-names>EJ</given-names>
            </name>
          </person-group>
          <article-title>Refinement of macromolecular structures by the maximum-likelihood method</article-title>
          <source>Acta. Crystallogr. D Biol. Crystallogr.</source>
          <year>1997</year>
          <volume>53</volume>
          <fpage>240</fpage>
          <lpage>255</lpage>
          <pub-id pub-id-type="doi">10.1107/S0907444996012255</pub-id>
          <?supplied-pmid 15299926?>
          <pub-id pub-id-type="pmid">15299926</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emsley</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lohkamp</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Cowtan</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Features and development of Coot</article-title>
          <source>Acta. Crystallogr. D Biol. Crystallogr.</source>
          <year>2010</year>
          <volume>66</volume>
          <fpage>486</fpage>
          <lpage>501</lpage>
          <pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id>
          <?supplied-pmid 20383002?>
          <pub-id pub-id-type="pmid">20383002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>VB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>MolProbity: all-atom structure validation for macromolecular crystallography</article-title>
          <source>Acta. Crystallogr. D Biol. Crystallogr.</source>
          <year>2010</year>
          <volume>66</volume>
          <fpage>12</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1107/S0907444909042073</pub-id>
          <?supplied-pmid 20057044?>
          <pub-id pub-id-type="pmid">20057044</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edgar</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>MUSCLE: multiple sequence alignment with high accuracy and high throughput</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2004</year>
          <volume>32</volume>
          <fpage>1792</fpage>
          <lpage>1797</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gkh340</pub-id>
          <?supplied-pmid 15034147?>
          <pub-id pub-id-type="pmid">15034147</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robert</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Gouet</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Deciphering key features in protein structures with the new ENDscript server</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2014</year>
          <volume>42</volume>
          <fpage>W320</fpage>
          <lpage>W324</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gku316</pub-id>
          <?supplied-pmid 24753421?>
          <pub-id pub-id-type="pmid">24753421</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niesen</surname>
              <given-names>FH</given-names>
            </name>
            <name>
              <surname>Berglund</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Vedadi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability</article-title>
          <source>Nat. Protoc.</source>
          <year>2007</year>
          <volume>2</volume>
          <fpage>2212</fpage>
          <lpage>2221</lpage>
          <pub-id pub-id-type="doi">10.1038/nprot.2007.321</pub-id>
          <?supplied-pmid 17853878?>
          <pub-id pub-id-type="pmid">17853878</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vivoli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Novak</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Littlechild</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Harmer</surname>
              <given-names>NJ</given-names>
            </name>
          </person-group>
          <article-title>Determination of protein-ligand interactions using differential scanning fluorimetry</article-title>
          <source>J. Vis. Exp.</source>
          <year>2014</year>
          <volume>91</volume>
          <fpage>51809</fpage>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>SmogyiI</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Notes on sugar determination</article-title>
          <source>J. Biol. Chem.</source>
          <year>1952</year>
          <volume>195</volume>
          <fpage>19</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="pmid">14938350</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>